These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30624737)

  • 1. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential.
    Maiden MM; Zachos MP; Waters CM
    J Antimicrob Chemother; 2019 Apr; 74(4):894-906. PubMed ID: 30624737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms.
    Maiden MM; Hunt AMA; Zachos MP; Gibson JA; Hurwitz ME; Mulks MH; Waters CM
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29661867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells.
    Moreau-Marquis S; Coutermarsh B; Stanton BA
    J Antimicrob Chemother; 2015 Jan; 70(1):160-6. PubMed ID: 25213272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.
    Yu Q; Griffin EF; Moreau-Marquis S; Schwartzman JD; Stanton BA; O'Toole GA
    J Antimicrob Chemother; 2012 Nov; 67(11):2673-81. PubMed ID: 22843834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
    Koeva M; Gutu AD; Hebert W; Wager JD; Yonker LM; O'Toole GA; Ausubel FM; Moskowitz SM; Joseph-McCarthy D
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
    Yadav R; Bulitta JB; Schneider EK; Shin BS; Velkov T; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 8. Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms.
    Haagensen J; Verotta D; Huang L; Engel J; Spormann AM; Yang K
    J Antimicrob Chemother; 2017 Dec; 72(12):3357-3365. PubMed ID: 28961810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms.
    Nagant C; Tré-Hardy M; El-Ouaaliti M; Savage P; Devleeschouwer M; Dehaye JP
    Appl Microbiol Biotechnol; 2010 Sep; 88(1):251-63. PubMed ID: 20625718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media.
    Thellin O; Zorzi W; Jolois O; Elmoualij B; Duysens G; Cahay B; Streel B; Charif M; Bastin R; Heinen E; Quatresooz P
    Int J Antimicrob Agents; 2015 Jul; 46(1):33-8. PubMed ID: 25963337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of L-arginine on cystic fibrosis
    Eisha S; Morris AJ; Martin I; Yau YCW; Grasemann H; Waters V
    Antimicrob Agents Chemother; 2024 Aug; 68(8):e0033624. PubMed ID: 39023260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model.
    Tré-Hardy M; Nagant C; El Manssouri N; Vanderbist F; Traore H; Vaneechoutte M; Dehaye JP
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4409-15. PubMed ID: 20696878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizations of the viability and gene expression of dispersal cells from Pseudomonas aeruginosa biofilms released by alginate lyase and tobramycin.
    Daboor SM; Raudonis R; Cheng Z
    PLoS One; 2021; 16(10):e0258950. PubMed ID: 34695148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine or nitrate enhances antibiotic susceptibility of Pseudomonas aeruginosa in biofilms.
    Borriello G; Richards L; Ehrlich GD; Stewart PS
    Antimicrob Agents Chemother; 2006 Jan; 50(1):382-4. PubMed ID: 16377718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
    Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa.
    Soren O; Rineh A; Silva DG; Cai Y; Howlin RP; Allan RN; Feelisch M; Davies JC; Connett GJ; Faust SN; Kelso MJ; Webb JS
    J Antimicrob Chemother; 2020 Jan; 75(1):117-125. PubMed ID: 31682251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
    Field TR; White A; Elborn JS; Tunney MM
    Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
    Breen SKJ; Harper M; López-Causapé C; Rogers KE; Tait JR; Smallman TR; Lang Y; Lee WL; Zhou J; Zhang Y; Bulitta JB; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
    Int J Antimicrob Agents; 2024 Jun; 63(6):107161. PubMed ID: 38561094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of antimicrobial activity against pseudomonas aeruginosa by coadministration of G10KHc and tobramycin.
    Eckert R; Brady KM; Greenberg EP; Qi F; Yarbrough DK; He J; McHardy I; Anderson MH; Shi W
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3833-8. PubMed ID: 16940063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.